Related Experiment Video
Updated: Mar 21, 2026
Dynamic Clamp Methods to Investigate Impaired Neuronal Excitability Associated with Autism
Published on: October 17, 2025
Emerging Discussions on Folinic Acid and Acetaminophen in Autism
Mustafa Balkanas1, Gizem Durcan2, Burak Doğangün2
1Department of Child and Adolescent Psychiatry, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098, Istanbul, Turkey. mustafa.balkanas@iuc.edu.tr.
Insights
Folinic acid shows limited evidence for autism symptom improvement, especially in specific subgroups. Prenatal acetaminophen exposure is not linked to autism risk in large sibling studies.
Area of Science:
- Neurodevelopmental disorders
- Pediatric neurology
- Pharmacology
Background:
- Autism Spectrum Disorder (ASD) diagnosis and management remain complex.
- Emerging research explores potential therapeutic interventions and environmental factors.
- Folinic acid and prenatal acetaminophen exposure are areas of recent investigation.
Purpose:
To provide a balanced update for clinicians and families on folinic acid (leucovorin) in autism and the evidence regarding prenatal acetaminophen (paracetamol) exposure.
Methods:
We summarise key randomised trials of folinic acid and the most methodologically rigorous observational evidence on prenatal acetaminophen, with attention to study design and subgroup findings.
Results:
Several small, randomised trials report short-term improvements in verbal or social communication with folinic acid. These effects appear stronger in biological subgroups, such as children with folate receptor autoantibodies (FRAA). However, the evidence remains limited due to small sample sizes, single-centre designs, and variable outcome measures. Notably, a randomised trial published in 2024 was retracted in January 2026, highlighting the need for caution regarding early findings. For acetaminophen, there is ongoing debate about its potential association with autism. A major Swedish cohort study using sibling control analysis (n = 2,480,797) found no association with autism, ADHD, or intellectual disability after adjusting for familial factors.
Conclusion:
Clear, evidence-based communication is essential to help families navigate emerging evidence without being misled by premature claims.
Related Concept Videos
01:19Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
01:24Phase II Reactions: Acetylation Reactions
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
01:24Drug Toxicity: Risk factors